Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.75 |
| ▸ | CDK1 | P06493 | 1/20 | 0.75 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.75 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.75 |
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | CNR1 | P21554 | 8/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | VDR | P11473 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aloisine B SCHEMBL29408792 | 0.86 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3CNR1 | |
| SCHEMBL7645847 | 0.85 | CCNB2 (0.57) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL11797871 | 0.85 | CCNB2 (0.57) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL10933044 | 0.85 | CCNB2 (0.61) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL11656880 | 0.84 | CCNB2 (0.55) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL11619004 | 0.81 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL21228922 | 0.81 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL16454909 | 0.79 | CNR1 (0.57) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL20104531 | 0.79 | CCNB2 (0.50) | CCNB2CDK1CCNB1CCNB3ESR1 | |
| SCHEMBL29090070 | 0.78 | ESR1 (0.52) | CCNB2CDK1CCNB1CCNB3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20210382392-A1 | HARD-MASK FORMING COMPOSITION AND METHOD FOR MANUFACTURING ELECTRONIC COMPONENT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20200223848-A1 | DEGRADATION AGENT USING AUTOPHAGIC MECHANISM OF DAMAGED MITOCHONDRIA | TOHOKU UNIVERSITY (JP) | 2020-07-16 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-8470889-B2 | Hybrid-ionone and curcumin molecules as anticancer agents | TRT PHARMA INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | TRT PHARMA INC. (CA) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | IKBKG, HSD17B11, IKBKE | CCNB2 1293/4885CDK1 953/4885CCNB1 648/4885 |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | HIPK1, PDXK, IP6K1 | CCNB2 2588/4885CDK1 349/4885CCNB1 2895/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CCNB2 3718/4885CDK1 576/4885CCNB1 3870/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CCNB2 2530/4885CDK1 620/4885CCNB1 2287/4885 |
| US-20200223848-A1 | DEGRADATION AGENT USING AUTOPHAGIC MECHANISM OF DAMAGED MITOCHONDRIA | HSPA9, ATG7, TFAM | CCNB2 3763/4885CDK1 3136/4885CCNB1 3906/4885 |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | CCNB2 2588/4885CDK1 349/4885CCNB1 2895/4885 |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | CCNB2 2588/4885CDK1 349/4885CCNB1 2895/4885 |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, SIK1 | CCNB2 1555/4885CDK1 174/4885CCNB1 1776/4885 |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, IP6K1, PDXK | CCNB2 2634/4885CDK1 465/4885CCNB1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.